Examkin

Soru

Zorluk: OrtaMonitoring and Treatment Evaluation

A 7272-year-old man is evaluated in the clinic for a routine follow-up. One week ago, he was started on oral amiodarone for the suppression of highly symptomatic, recurrent atrial fibrillation. His other medical conditions include hypertension, hyperlipidemia, and type 2 diabetes mellitus. His current medications include lisinopril, simvastatin 80 mg80\text{ mg} daily, and metformin. He feels well and reports no new symptoms. As part of the ongoing monitoring and treatment evaluation plan for this patient, which of the following are appropriate management steps? (Select all that apply)

  1. Perform baseline and periodic assessment of thyroid-stimulating hormone (TSH) levelsCevap
  2. Obtain a baseline chest radiograph and periodically evaluate for pulmonary toxicityCevap
  3. C
    Maintain the current simvastatin dosage, as there are no clinically significant pharmacokinetic interactions to address
  4. D
    Order a baseline high-resolution computed tomography (HRCT) scan of the chest to definitively exclude underlying interstitial lung disease
  5. E
    Plan to discontinue the antiarrhythmic agent immediately if asymptomatic, 1.51.5-fold elevations in serum aminotransferases are detected

Cevap

The appropriate management steps are to perform baseline and periodic assessment of thyroid-stimulating hormone (TSH) levels and to obtain a baseline chest radiograph to evaluate for pulmonary toxicity.
Amiodarone is a highly efficacious antiarrhythmic agent with a complex safety profile involving substantial end-organ toxicities and drug interactions. Standard of care for monitoring its use includes baseline and periodic evaluation of thyroid function (TSH) because its high iodine content and intrinsic mechanisms can induce either hyperthyroidism or hypothyroidism. Additionally, baseline pulmonary screening with a chest radiograph is mandated to monitor for amiodarone-induced interstitial pneumonitis, a potentially fatal complication.

Adım Adım Çözüm

1
Identify the high-risk pharmacotherapy recently initiated.
The patient was started on amiodarone, a class III antiarrhythmic with significant multi-organ toxicities and profound drug-drug interactions.
Recognizing the safety profile of amiodarone dictates the necessary baseline monitoring and treatment adjustments.
2
Determine the standard screening and monitoring requirements for amiodarone.
Baseline evaluation of hepatic (LFTs), thyroid (TSH), pulmonary (CXR/PFTs), and ophthalmic function is required to establish a baseline and monitor for ongoing drug toxicity.
Amiodarone can cause fatal pulmonary fibrosis, thyroid dysfunction, and hepatotoxicity; establishing a baseline is critical for longitudinal treatment evaluation.
3
Evaluate the patient's existing medication regimen for potential interactions with the new agent.
The patient is taking high-dose simvastatin (80 mg80\text{ mg}). Amiodarone inhibits CYP3A4, which significantly increases simvastatin serum concentrations.
Failing to adjust the simvastatin dose (maximum recommended dose with amiodarone is 20 mg20\text{ mg}/day) drastically increases the risk of rhabdomyolysis. Therefore, maintaining the current dose is incorrect.

Anahtar Kavram

Patients initiating amiodarone therapy require rigorous baseline and periodic monitoring of pulmonary, thyroid, and hepatic function, alongside careful review of drug interactions (e.g., CYP3A4 inhibition affecting statins).
Bu soruyu puanla

Konular

Monitoring and Treatment Evaluation

Bu konudan daha fazla soru